miR-221/222 sponge abrogates tamoxifen resistance in ER-positive breast cancer cells through restoring the expression of ERα
Open Access
- 30 June 2021
- journal article
- research article
- Published by Springer Nature in Molecular Biomedicine
- Vol. 2 (1) , 1-11
Abstract
Tamoxifen resistance (TamR) prevents ER-positive breast cancer patients from benefitting from endocrine therapy, and miR-221 or miR-222 plays vital roles in inducing TamR. In this study, we designed synthetic sponges to reverse TamR by targeting these two miRs. First, we established a tamoxifen resistant breast cancer cell line (MCF-7TamR), we verified the high expressing level of these two miRs in TamR cells. miR-221 or miR-222 inhibitors rendered MCF-7TamR cells responsive to tamoxifen. Next, we designed a miR-221/222 sponge, which contains total 8 multi-antisense binding sites (MBSs) for these two onco-miRs, and inserted it into CMV promoter- or hTERT promoter-driven expressing vectors. After transfected miR-221/222 sponge expressing vectors into MCF-7TamR cells, we identified a strong interaction between miR-221/222 sponge and endogenous miR-221 or miR-222 by RNA pulldown assay. We also found that miR-221/222 sponge restored the expression of ERα and PTEN, arrested cells in G1 phase, and finally resulted in reduced cell growth and cell migration. Notably, miR-221/222 sponge expressing cells abrogates tamoxifen resistance through restoring the expression of ERα, suggesting that miR-221/222 sponge gene therapy especially driven by tumor specific promoter could provide an effective therapeutic approach against TamR in breast cancer.Keywords
Funding Information
- The National Natural Science Foundation of China (91859120)
- Natural Science Foundation of Guangdong Province (2016A030312008)
- Scientific Research Fund of Traditional Chinese Medicine Bureau of Guangdong Province (20181146)
- Start-Up Fund for High-Talents from Xiang’an Hospital of Xiamen University (PM201809170013)
- The Science and Technology Plan Project of Shenzhen municipality (JCYJ20160429172031572)
This publication has 42 references indexed in Scilit:
- Rapid Generation of MicroRNA Sponges for MicroRNA InhibitionPLOS ONE, 2012
- Anti-microRNA-222 (Anti-miR-222) and -181B Suppress Growth of Tamoxifen-resistant Xenografts in Mouse by Targeting TIMP3 Protein and Modulating Mitogenic SignalJournal of Biological Chemistry, 2011
- Mechanisms of Endocrine Resistance in Breast CancerAnnual Review of Medicine, 2011
- MicroRNA sponges: Progress and possibilitiesRNA, 2010
- MicroRNA Cluster 221-222 and Estrogen Receptor α Interactions in Breast CancerJNCI: Journal of the National Cancer Institute, 2010
- RETRACTED: miR-221&222 Regulate TRAIL Resistance and Enhance Tumorigenicity through PTEN and TIMP3 DownregulationCancer Cell, 2009
- A novel hTERT promoter–driven E1A therapeutic for ovarian cancerMolecular Cancer Therapeutics, 2009
- MicroRNAs As Novel Regulators of AngiogenesisCirculation Research, 2009
- MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1Journal of Biological Chemistry, 2008
- Tamoxifen: a most unlikely pioneering medicineNature Reviews Drug Discovery, 2003